Mentor, Shireen2023-01-112023-01-112019Raikwar, S. P. et al. (2019). Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders. J Neuroimmune Pharmacol 14, 608–641 (2019). https://doi.org/10.1007/s11481-019-09849-y1557-1890http://hdl.handle.net/10566/8263Despite significant advancements in the field of molecular neurobiology especially neuroinflammation and neurodegeneration, the highly complex molecular mechanisms underlying neurodegenerative diseases remain elusive. As a result, the development of the next generation neurotherapeutics has experienced a considerable lag phase. Recent advancements in the field of genome editing offer a new template for dissecting the precise molecular pathways underlying the complex neurodegenerative disorders. We believe that the innovative genome and transcriptome editing strategies offer an excellent opportunity to decipher novel therapeutic targets, develop novel neurodegenerative disease models, develop neuroimaging modalities, develop next-generation diagnostics as well as develop patient-specific precision-targeted personalized therapies to effectively treat neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis, Frontotemporal dementia etcen-USAlzheimer’s diseaseAmyotrophic lateral sclerosisCRISPRFrontotemporal dementiagenome editingNext generation precision medicine: Crispr-mediated genome editing for the treatment of neurodegenerative disordersArticle